Assay In Which A Label Present Is An Enzyme Substrate Or Substrate Analogue Patents (Class 435/7.72)
-
Patent number: 6946547Abstract: The present invention provides a system for the improved detection of ecstasy-class compounds in biological samples. New ecstasy-class analogs are provided for detection of such ecstasy-class drugs. These analogs are compounds, or salts thereof, of a 2-amino-methylenedioxyphenyl (MDP) derivative attached to Z, where Z is a moiety capable of bonding, either directly or indirectly, with an immunogenic carrier, a detectable label, or a solid capture vehicle. Such analogs may be used to construct immunogens, enzyme or enzyme-donor conjugates, and other conjugates. The immunogens reproducibly generate antibodies with an exquisite ability to distinguish various ecstasy-class drugs in biological samples from potentially interfering substances. The specific antibodies and the conjugates may be used to distinguish and measure various ecstasy-class compounds in biological samples, such as those obtained from an individual suspected of substance abuse.Type: GrantFiled: June 9, 2003Date of Patent: September 20, 2005Assignee: Microgenics CorporationInventors: Riaz Rouhani, Anthony de Jesus Sanchez, David Davoudzadeh, William A. Coty, Cynthia A. Vistica
-
Patent number: 6939720Abstract: A method for the multiplexed diagnostic and genetic analysis of enzymes, DNA fragments, antibodies, and other biomolecules comprises the steps of constructing an appropriately labeled beadset, exposing the beadset to a clinical sample, and analyzing the combined sample/beadset by flow cytometry. Flow cytometric measurements are used to classify, in real-time, beads within an exposed beadset and textual explanations, based on the accumulated data obtained during real-time analysis, are generated for the user. The inventive technology enables the simultaneous, and automated, detection and interpretation of multiple biomolecules or DNA sequences in real-time while also reducing the cost of performing diagnostic and genetic assays.Type: GrantFiled: December 27, 2002Date of Patent: September 6, 2005Assignee: Luminex CorporationInventors: Van S. Chandler, R. Jerrold Fulton, Mark B. Chandler
-
Patent number: 6936687Abstract: The present invention provides for novel reagents whose fluorescence increases in the presence of particular proteases. The reagents comprise a characteristically folded peptide backbone each end of which is conjugated to a fluorophore. When the folded peptide is cleaved, as by digestion with a protease, the fluorophores provide a high intensity fluorescent signal at a visible wavelength. Because of their high fluorescence signal in the visible wavelengths, these protease indicators are particularly well suited for detection of protease activity in biological samples, in particular in frozen tissue sections. Thus this invention also provides for methods of detecting protease activity in situ in frozen sections.Type: GrantFiled: September 10, 1999Date of Patent: August 30, 2005Assignee: Onco Immunin, Inc.Inventors: Akira Komoriya, Beverly S. Packard
-
Patent number: 6936423Abstract: Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the first fifteen amino acids of LTNF-n is: Leu Lys Ala Met Asp Pro Thr Pro Pro Leu Trp Ile Lys Thr Glu. Antibodies to LTNF-n and synthetic peptides consisting of fifteen, ten and five amino acids from the N-terminal of the above sequence, designated as LTNF-15, LTNF-10 and LTNF-5 were produced by immunizing Balb/C mice to produce Anti-LTNF-n, Anti-LTNF-15, Anti-LTNF-10 and Anti-LTNF-5. The anti LTNF-n, anti-LTNF-15, anti-LTNF-10 and anti-LTNF-5 react immunologically with all types of toxins derived from animal, plant and bacteria and can be assayed by immunological in vitro test such as ELISA tests. Anti-LTNFs react roughly proportional to lethal dose of biological toxins under in vitro immunological ELISA test similar to the mouse bioassay test.Type: GrantFiled: April 27, 1999Date of Patent: August 30, 2005Inventors: Binie V. Lipps, Frederick W. Lipps
-
Patent number: 6921634Abstract: The present invention provides a replication competent hepatitis C virus that includes a heterologous polynucleotide. The invention also includes methods for modifying a hepatitis C virus polynucleotide, selecting a replication competent hepatitis C virus polynucleotide, detecting a replication competent hepatitis C virus polynucleotide, and identifying a compound that inhibits replication of a hepatitis C virus polynucleotide.Type: GrantFiled: September 27, 2002Date of Patent: July 26, 2005Assignee: Board of Regents, The University of Texas SystemInventors: Stanley M. Lemon, MinKyung Yi
-
Patent number: 6921669Abstract: The present invention relates to a linker system for activating surfaces for bioconjugation, and particularly to a linker system having a novel hydrophilic spacer group. The inventive linker system may be used for the construction of sensor chips or biochips for the detection of sample biomolecules.Type: GrantFiled: May 16, 2001Date of Patent: July 26, 2005Assignee: Micronas Holding GmbHInventor: Holger Klapproth
-
Patent number: 6913935Abstract: A method for the assay of N samples each containing a compound to be tested, comprises providing N reaction vessels each containing a population of carrier beads and other reagents for performing the assay, where N is at least 2 e.g. 80-4000. Each population of carrier beads is distinguishable from every other population. After adding the samples to the reaction vessels and performing the assays, the contents of all the reaction vessels are mixed and subjected to analysis by flow cytometry. By means of flow cytometry, each carrier bead is rapidly analysed to identify its population and also to determine the presence or concentration or biological activity of the compound to be tested.Type: GrantFiled: December 3, 1998Date of Patent: July 5, 2005Assignee: Amersham Biosciences UK LimitedInventor: Nicholas Thomas
-
Patent number: 6913895Abstract: This invention relates to the field of bacterial transglycosylase reactions. The invention is directed to methods for assaying for transglycosylase activity, methods of identifying inhibitors of transglycosylase activity, inhibitors identified by such methods, and methods of identifying the stage of inhibition at which such inhibitors act.Type: GrantFiled: August 17, 1999Date of Patent: July 5, 2005Assignee: Advanced Medicine East, Inc.Inventors: Robert C. Goldman, Arthur A. Branstrom
-
Patent number: 6893868Abstract: The present invention provides for novel reagents whose fluorescence changes upon cleavage or a change in conformation of a backbone. The reagents comprise a backbone (e.g. nucleic acid, polypeptide, etc.) joining two fluorophores of the same species whereby the fluorophores form an H-dimer resulting in quenching of the fluorescence of the fluorophores. When the backbone is cleaved or changes conformation, the fluorophores are separated, no longer forming an H-type dimer, and are de-quenched thereby providing a detectable signal. The use of a single fluorophore rather than an “acceptor-donor” fluoresecence resonance energy transfer system offers synthesis and performance advantages.Type: GrantFiled: December 22, 2000Date of Patent: May 17, 2005Assignee: Onco Immunin, Inc.Inventors: Beverly Packard, Akira Komoriya
-
Patent number: 6887712Abstract: A method is disclosed for determining whether a compound binds to a lipoprotein such as LDL or VLDL in a manner which will lower plasma cholesterol. The method provided includes assessing the ability of the compound to form a complex with the lipoprotein, and then determining whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to an LDL receptor.Type: GrantFiled: November 9, 1999Date of Patent: May 3, 2005Assignee: AtheroGenics, Inc.Inventors: Russell M. Medford, Uday Saxena
-
Patent number: 6875750Abstract: Aziridine derivatives of formula (I) are disclosed which can be used as cofactor for S-adenosyl-L-methionine-dependent methyltransferases.Type: GrantFiled: July 28, 1999Date of Patent: April 5, 2005Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.Inventors: Marc Pignot, Elmar Weinhold
-
Patent number: 6875581Abstract: A method for screening of modulators of calcineurin is provided, which uses the interaction between calcineurin and superoxide dismutase. Modulators of calcineurin are potential candidates for drugs, e.g. for immunosuppressive drugs. The forming of a complex comprising calcineurin and superoxide dismutase is monitorable in the presence of potential activators or inhibitors of calcineurin. Complex formation is performed within the cell by the use of appropriate expression vectors or in vitro using isolated proteins. Preferably, complex formation is monitored by fluorescence detection, especially by laser fluctuation correlation spectroscopy.Type: GrantFiled: July 22, 1999Date of Patent: April 5, 2005Assignee: Genopia Biomedical GmbHInventor: Helge Voelkel
-
Patent number: 6872540Abstract: A method and apparatus for the differentiation of Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome, using the presence of fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as a marker for Crohn's disease are provided. The apparatus includes an enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous ASCA in a human fecal sample. The method and apparatus may be used by healthcare providers to distinguish Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome.Type: GrantFiled: October 25, 2002Date of Patent: March 29, 2005Assignee: Techlab, Inc.Inventors: James Hunter Boone, David Maxwell Lyerly, Tracy Dale Wilkins
-
Patent number: 6872543Abstract: The present invention concerns a method for assessing the risk of peptic ulcer by determining the presence and topographic phenotype of gastritis in an individual, by determining quantitatively the pepsinogen I and gastin-17 concentrations in a serum sample from the said individual, selecting a method-specific reference value and cut-off value for respective analyte, assessing the topography and phenotype of gastritis based on a comparison of the pepsinogen I and gastrin-17 concentrations so determined with their respective method-specific reference and cut-off values, and correlating the so assessed gastritis phenotype with the risk for peptic ulcer. Preferably also Helicobacter antibodies are determined in the sample.Type: GrantFiled: April 28, 2000Date of Patent: March 29, 2005Assignee: Biohit OyjInventors: Pentti Sipponen, Matti Härkönen, Osmo Suovaniemi, Erik Forsblom
-
Patent number: 6844167Abstract: This invention provides the genes encoding the RNA triphosphatase and RNA guanylyltransferase of the malaria parasite Plasmodium falciparum and the catalytically active recombinant RNA triphosphatase and RNA guanylyltransferase enzymes. These enzymes form the basis of activity inhibition assays to identify molecules that specifically target the formation of the mRNA 5? cap in unicellular eukaryotic parasites.Type: GrantFiled: June 12, 2002Date of Patent: January 18, 2005Inventors: Stewart Shuman, Chong Kiong Ho
-
Patent number: 6844162Abstract: A method and kit for monitoring autoantibodies to thyroid stimulating hormone (TSH) receptor in a sample of body fluid, which employs the steps of: (i) incubating TSH receptor with a sample of body fluid; (ii) reacting the incubated sample of body fluid with at least one binding agent which is capable of binding to the TSH receptor in competitive reaction with TSH receptor autoantibodies (TRAb), or in a case where TSH receptor is complexed to labelled antibody, reacting the sample of body fluid with at least one binding agent which can bind to TRAb in such a way as not substantially to interfere with binding of the TRAb to the TSH receptor; and (iii) detecting bound TRAb in the reacted incubated sample of body fluid.Type: GrantFiled: January 31, 2000Date of Patent: January 18, 2005Assignee: RSR LimitedInventors: Bernard Rees Smith, Jane Sanders, Jadwiga Furmaniak
-
Patent number: 6828091Abstract: A method for identifying therapeutically effective immunosuppressive agents by screening such agents for those which induce apoptosis in activated T cells is disclosed. T cells were isolated then activated and treating with various test compounds. A caspase substrate is added to detect caspase activation and apoptosis in the cells. Compounds which stimulate caspase activation and apoptosis are also tested against resting T cells to determine those agents which are more effective in activated T cells compared to resting T cells. Compounds with this selectivity are effective in treating immunopathological disorders such as arthritis, graft rejection, graft versus host disease, inflammatory bowel syndrome and the like.Type: GrantFiled: August 2, 2001Date of Patent: December 7, 2004Assignee: Cytovia, Inc.Inventors: Shailaja Kasibhatla, Douglas R. Green, Ben Tseng
-
Patent number: 6828116Abstract: Disclosed is a non-fluorescent cyanine dye that may be used as an acceptor in fluorescence energy transfer assays involving the detection of binding and/or cleavage events in reactions involving biological molecules, and assay methods utilising such dyes.Type: GrantFiled: February 15, 2001Date of Patent: December 7, 2004Assignee: Amersham Biosciences UK LimitedInventors: Alan L. Hamilton, Martyn N. Birch, Malcolm J. Hatcher, Nigel Bosworth, Brian Scott
-
Patent number: 6824998Abstract: The present invention provides compounds useful for the detection of the enzyme tripeptidyl protease I (TPP-1). The invention also provides methods of making such compounds, methods of using such compounds, and kits and compositions containing such compounds. In one embodiment, Gly-L-Pro-L-Ser-1-anthraquinonylhydrazide, in combination with p-anisaldehyde, is used to detect TPP-1.Type: GrantFiled: March 19, 2003Date of Patent: November 30, 2004Assignee: University of Iowa Research FoundationInventors: Beverly L. Davidson, David Wiemer
-
Patent number: 6808939Abstract: Bipyridine or phenanthroline ligands presenting functional groups that prevent non-specific binding (in particular, negatively charged functional groups that are unaffected by standard conditions for conjugating biological reagents through amide bonds) are described as are luminescent metal complexes comprising these ligands. The use of luminescent ruthenium and osmium complexes comprising these ligands in electrochemiluminescence assays shows that the use of these labels can significantly reduce the amount of non-specific binding observed relative to assays carried out using reagents labeled with analogous labels that don't present functional groups that decrease non-specific binding.Type: GrantFiled: June 29, 2001Date of Patent: October 26, 2004Assignees: IGEN International, Inc., BioVeris CorporationInventors: George B. Sigal, Howie Tjiong, Liwen Dong, Md. Athar Masood, Richard C. Titmas
-
Patent number: 6805852Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO.Type: GrantFiled: March 26, 2002Date of Patent: October 19, 2004Assignee: Cedars-Sinai Medical CenterInventors: Henry C. Lin, Mark Pimentel
-
Patent number: 6803188Abstract: This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.Type: GrantFiled: January 31, 1996Date of Patent: October 12, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, Roger Heim
-
Patent number: 6794156Abstract: A competitive assay to determine the presence and concentration of an intracellular analyte (e.g., cAMP) in a sample is provided. All of the steps of the assay can be performed on the same assay plate, thereby eliminating the need to transfer the cells from a tissue culture plate on which the cells are grown, induced and lysed to a separate assay plate. The assay procedure includes combining, in a reaction chamber provided with a capture antibody, an antibody for the analyte, the sample to be assayed, and a conjugate of the analyte and an enzyme such as alkaline phosphatase. The mixture is incubated and washed and an enzyme labile substrate (e.g., a chemiluminescent, fluorescent or calorimetric substrate) is added. The assay can also be performed with a tagged analyte (e.g., an analyte having a radioactive or fluorescent tag) instead of an enzyme conjugate.Type: GrantFiled: April 18, 2002Date of Patent: September 21, 2004Assignee: Applera CorporationInventor: Anthony C. Chiulli
-
Patent number: 6787325Abstract: Provided are novel complexes containing a crosslinked avidin, an analyzing method and analyzing reagents and kits whereby a compound to be analyzed can be quickly, conveniently and accurately analyzed while taking advantage of the avidin-biotin reaction. The complexes contain at least two homogeneous or heterogeneous biotin-introduced products and one crosslinked avidin sandwiched therebetween. In the analyzing method, the homogeneous or heterogeneous biotin-introduced products and the crosslinked avidin are used. The analyzing reagent contains the crosslinked avidin. The analyzing kit contains the crosslinked avidin and a biotinylating agent.Type: GrantFiled: July 5, 2000Date of Patent: September 7, 2004Assignees: Iatron Laboratories, Inc., Kikkoman CorporationInventors: Kazuyuki Sugiyama, Nobuhiro Hoshino, Hiroki Tatsumi, Satoshi Fukuda
-
Patent number: 6764823Abstract: The present invention provides methods of identifying antimicrobial agents that target genes essential for the survival of Staphylococcus bacteria, including antimicrobial agents that interfere with the expression of essential coding sequence products and antimicrobial agents that interfere with the function of essential coding sequence products.Type: GrantFiled: April 6, 2001Date of Patent: July 20, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Che-Shen C. Tomichi, Cheryl Quinn, Staffan Arvidson
-
Patent number: 6764817Abstract: The present invention provides methods and apparatus for purifying metabolites of interest and conducting metabolic analyses. The methods generally involve determining metabolic flux values for a plurality of target analytes by monitoring the relative isotope abundance of a stable isotope in a substrate labeled with the stable isotope and/or one or more target metabolites formed through metabolism of the labeled substrate. Certain methods utilize multiple electrophoretic methods to separate the target analytes from other components within the sample being analyzed. The methods can be used in a variety of applications including screens to identify metabolites that are correlated with certain diseases and diagnostic screens for identifying individuals having, or susceptible to, a disease.Type: GrantFiled: April 19, 2000Date of Patent: July 20, 2004Assignee: Target Discovery, Inc.Inventor: Luke V. Schneider
-
Patent number: 6762033Abstract: Disclosed is a method for determining the fertility of mammals, in particular of humans, wherein a body or organ fluid is taken from a mammal, the afamin content is determined in this body or organ fluid, and the determined afamin content is compared with a reference value so as to determine the fertility, the use of afamin for determining the fertility of mammals, as well as a kit for carrying out this method.Type: GrantFiled: December 21, 2001Date of Patent: July 13, 2004Assignee: Vitateq Biotechnology GmbHInventors: Karl Oskar Illmensee, Hans Dieplinger
-
Patent number: 6762280Abstract: In this application is described substrates for high-throughput assays of clostridial neurotoxin proteolytic activities. Two types of substrates are described for use in assays for the proteolytic activities of clostridial neurotoxins: (1) modified peptides or proteins that can serve as FRET substrates and (2) modified peptides or proteins that can serve as immobilized substrates. In both types a fluorescent molecules is present in the substrate, eliminating the requirement for the addition of a fluorigenic reagent. The assays described can be readily adapted for use in automated or robotic systems.Type: GrantFiled: September 25, 2001Date of Patent: July 13, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventors: James J. Schmidt, Robert G. Stafford
-
Patent number: 6759189Abstract: The present invention relates generally to lysosomal storage disorders and to diagnostic agents for their detection in humans and other animals. More particularly, the present invention is directed to the uses of the LSD markers Lamp-1, Lamp-2, Limp-II, 4-sulphatase, acid phosphatase (ACP), &bgr;-hexosaminidase or &agr;-mannosidase, amongst others as diagnotic agents for the detection of many lysosomal storage disorders.Type: GrantFiled: November 12, 1998Date of Patent: July 6, 2004Assignee: Women's and Children's HopitalInventors: Peter J Meikle, Douglas A Brooks, John J Hopwood
-
Patent number: 6743591Abstract: A method for counting leukocytes which comprises liberating elastase from granulocytes contained in a specimen, adding an anti-granulocyte elastase antibody to the thus liberated elastase, measuring the antibody bonded to the elastase to thereby determine the concentration of the elastase, and then calculating therefrom the number of leukocytes contained in the specimen with the use of the ratio of the leukocyte count to the elastase concentration. This method makes it possible to conveniently and less expensively count leukocytes at a high accuracy comparable to the one established by using a conventional automatic blood cell counter, as the figure shows.Type: GrantFiled: August 31, 2000Date of Patent: June 1, 2004Assignee: Arkray, Inc.Inventors: Akio Okubo, Shigeki Yamada
-
Patent number: 6696262Abstract: Method for screening the risk for gastric cancer using, in combination, the determination of serum pepsinogen I, gastrin-17 and the supporting determination of Helicobacter pylori antibodies from blood serum, in order to detect either atrophy of the corpus area, atrophy of the antrum area or atrophy of the mucosa of the whole stomach as well as a causative Helicobacter pylori infection, whereby the risk for gastric cancer can be evaluated and the necessary gastroscopy and follow-up can be planned.Type: GrantFiled: March 14, 2001Date of Patent: February 24, 2004Assignee: Biohit OyjInventor: Matti Härkönen
-
Patent number: 6686171Abstract: A competitive assay for the concentration of a cyclic nucleotide such as cyclic adenosine monophosphate combines, in a reaction chamber provided with a capture antibody, an antibody for the cAMP or other cyclic nucleotide, the sample to be assayed and a conjugate of cAMP and alkaline phosphatase. The mixture is incubated and washed, and after washing, a 1,2-dioxetane which is caused to decompose when contacted by the alkaline phosphatase of said conjugate is added. The light emission caused by decomposition is measured, with the strength of the signal being inversely related to the concentration of the cyclic nucleotide. Optionally, an enhancement agent in the form of a polymeric onium salt may be added, to further enhance the light emission.Type: GrantFiled: May 10, 1999Date of Patent: February 3, 2004Assignee: Tropix, Inc.Inventors: Irena Y. Bronstein, Anthony C. Chiulli, Michelle A. J. Palmer, John C. Voyta
-
Patent number: 6670115Abstract: The present invention relates to devices comprising electrosensors containing capture reagents, their preparation thereof, and their use for detecting, preferably, quantitative measurement, of analyte in a liquid sample. In particular, the invention relates to an enzyme electrosensor, e.g., electroimmunosensor, device for electrochemical detection and preferably, real-time measurement, which is suitable for use at point-of-care settings by unskilled personnel.Type: GrantFiled: October 27, 2000Date of Patent: December 30, 2003Assignee: BioTronic Technologies, Inc.Inventor: Honghua Zhang
-
Patent number: 6670198Abstract: A test piece for use in biological analyses includes a plurality of different known specific binding substances disposed in predetermined positions on a substrate. The specific binding substances are disposed on a plurality of surfaces provided by the substrate and arranged in the direction of thickness of the substrate.Type: GrantFiled: May 8, 2001Date of Patent: December 30, 2003Assignee: Fuji Photo Film Co., Ltd.Inventor: Toshihito Kimura
-
Patent number: 6656699Abstract: The present invention is directed to compositions and methods for measuring enzymatic activity, particularly glycosidase activity. Methods of the present invention include assays for quantitatively determining the amount of glycosidase activity in a sample. The present invention also provides methods for the diagnosis of metastatic and inflammatory processes in vitro and in vivo. The present invention further provides compositions and methods for high throughput assays for identifying compounds that effect glycosidase activity.Type: GrantFiled: September 14, 2001Date of Patent: December 2, 2003Assignee: Reddy US Therapeutics, Inc.Inventors: Sivaram Pillarisetti, Uday Saxena, Dongyan Wang
-
Patent number: 6656696Abstract: This invention relates to methods and compositions for monitoring the interaction of binding partners as a function of the addition or subtraction of a phosphate group to or from one of the binding partners by a protein kinase or phosphatase.Type: GrantFiled: February 26, 1999Date of Patent: December 2, 2003Assignee: CyclacelInventors: Roger K. Craig, John Colyer
-
Patent number: 6653089Abstract: The present invention is directed, in certain embodiments, to improved, small scale systems and methods able to selectively treat parts of a single cell, including, in certain embodiments, portions of a main body portion of a single cell, and able, in certain embodiments, to establish long-term gradients of active substances within subcellular regions of a single cell. The present invention provides, in some embodiments, techniques for selectively contacting a portion of the surface of a biological cell with a fluid or fluid component carrying a particular potential for a biophysical or biochemical interaction with the cell, and simultaneously contacting a different portion of the surface of the cell with another fluid or fluid component having a different potential for the biophysical or biochemical interaction with the cell.Type: GrantFiled: September 18, 2001Date of Patent: November 25, 2003Assignees: President and Fellows of Harvard College, Children's Medical Center CorporationInventors: Shuichi Takayama, Emanuele Ostuni, Philip LeDuc, Keiji Naruse, Donald E. Ingber, George M. Whitesides
-
Patent number: 6649364Abstract: The present invention provides methods and compositions for modulating the apoptotic activity of interleukin-1&bgr; converting enzyme (ICE). The present invention further provides methods and compositions for alleviating pathological conditions associated with apoptotic mechanisms.Type: GrantFiled: June 7, 1995Date of Patent: November 18, 2003Assignee: The Regents of the University of CaliforniaInventors: Dale E. Bredesen, Celik Kayalar
-
Patent number: 6632682Abstract: An immunochemical method for the determination of antibodies which are specific for an antigen and are of one of the immunoglobulin classes: A, M, D or E in a fluid, with this fluid being contacted with a solid phase to which the antibodies against this immunoglobulin class, or a fragment of an antibody of this type, are bound, which results in the immunoglobulin of this class being bound to this solid phase, and this solid phase being contacted with the antigen, which carries a labeling means where appropriate, and with a labeled antibody or a labeled fragment of an antibody against the antigen if the antigen is unlabeled and determination, from the amount of labeling means which is bound to the solid phase, of the amount of these antibodies which are specific for an antigen and are one of the immunoglobulin classes, which comprises the solid phase being simultaneously in contact with the fluid containing the antibody which is to be determined and with the antigen, which is labeled where appropriate, there bType: GrantFiled: May 22, 1995Date of Patent: October 14, 2003Assignee: Dade Behring Marburg GmbHInventor: Robert Ziegelmaier
-
Publication number: 20030187247Abstract: The present invention describes human monoclonal antibodies which immunoreact with and neutralize human immunodeficiency virus (HIV). Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell line for producing the monoclonal antibodies.Type: ApplicationFiled: December 12, 2001Publication date: October 2, 2003Applicant: The Scripps Research InstituteInventors: Dennis R. Burton, Carlos F. Barbas, Richard A. Lerner
-
Patent number: 6627400Abstract: Families of compositions are provided as labels, referred to as eTag reporters for attaching to polymeric compounds and assaying based on release of the eTag reporters from the polymeric compound and separation and detection. For oligonucleotides, the eTag reporters are synthesized at the end of the oligonucleotide by using phosphite or phosphate chemistry, whereby mass-modifying regions, charge-modifying regions and detectable regions are added sequentially to produce the eTag labeled reporters. By using small building blocks and varying their combination large numbers of different eTag reporters can be readily produced attached to a binding compound specific for the target compound of interest for identification. Protocols are used that release the eTag reporter when the target compound is present in the sample.Type: GrantFiled: October 27, 2000Date of Patent: September 30, 2003Assignee: Aclara Biosciences, Inc.Inventors: Sharat Singh, Tracy Matray
-
Patent number: 6605441Abstract: The present invention relates to a novel human protein called Fibroblast Growth Factor 11, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.Type: GrantFiled: May 16, 2000Date of Patent: August 12, 2003Assignee: Human Genome Sciences, Inc.Inventors: Ralph Alderson, Robert J. Melder, Roxanne D. Duan, Craig A. Rosen, Jing-Shan Hu
-
Patent number: 6602716Abstract: A method and device for fluorimetric determination of a biological, chemical or physical parameter of a sample utilize at least two different luminescent materials, the first of which is sensitive to the parameter, at least with respect to luminescence intensity, and the second of which is insensitive to the parameter, at least with respect to luminescence intensity and decay time. The luminescent materials have different decay times. The time- or phase behaviour of the resulting luminescence response is used to form a reference value for determination of a parameter.Type: GrantFiled: April 10, 2000Date of Patent: August 5, 2003Assignee: PreSens Precision Sensing GmbHInventor: Ingo Klimant
-
Patent number: 6599756Abstract: Methods of detecting antibodies to one or more glycosphingolipid(s) of interest in a sample are disclosed which comprise using a solid-phase reactant having carbonyl groups attached thereon, and the glycosphingolipid(s) of interest linked to the solid-phase reactant by an amide bond between an amino group of the glycosphingolipid of interest and a carbonyl group attached to the solid-phase reactant. The methods of detecting antibodies to glycosphingolipid(s) of interest can be used in methods of diagnosing autoimmune diseases in an individual.Type: GrantFiled: July 27, 2000Date of Patent: July 29, 2003Assignee: Athena Diagnostics, Inc.Inventors: Normand J. Robichaud, Louis P. Kertiles
-
Patent number: 6596497Abstract: A method for the screening of antiviral compounds targeted to the HIV gp41 core structure comprising capturing polyclonal antibodies from an animal other than a mouse directed against a trimer of a heterodimer containing an N-peptide and a C-peptide onto a solid-phase, mixing a compound to be tested with an N-peptide and then adding a C-peptide, adding the resultant mixture to the resultant polyclonal antibody coated solid-phase and then removing unbound peptides and unbound compound, adding a monoclonal antibody directed against the trimer of a heterodimer containing an N-peptide and a C-peptide and measuring the antibody binding of the monoclonal antibody.Type: GrantFiled: March 14, 2000Date of Patent: July 22, 2003Assignee: New York Blood Center, Inc.Inventors: Shibo Jiang, Asim K. Debnath
-
Patent number: 6593079Abstract: The invention concerns a process for diagnosis of an HIV infection by means of an immunoassay using the specific detection of the p24 antigen of HIV1, HIV1-Sub0 and/or the p26 antigen of HIV2, at least one antibody against the env region of HIV1, HIV1-Sub0 and/or of HIV2 and at least one antibody against the pol and/or gag region of HIV1, HIV1-Sub0 and/or HIV2, reagent kits and test strips suitable for diagnostic procedure as well as monoclonal antibodies against p24 and their use.Type: GrantFiled: January 12, 2000Date of Patent: July 15, 2003Assignee: Roche Diagnostics GmbHInventors: Frederic Donie, Elke Faatz, Barbara Upmeier, Eva Hoess, Marie-Ange Buyse, Eric Saman
-
Patent number: 6589753Abstract: An improved method of performing immunohistochemical staining on a tissue sample to determine the presence of cytoplasmic tumor marker Metallopanstimulin in cells in the tissue sample. The method consists of generally of collecting the tissue sample; fixing the tissue sample in a manner that preserves the Metallopanstimulin in the cytoplasm of the tissue cells; embedding the sample in paraffin; deparaffinizing the tissue; heating the sample to expose antigenic sites; incubating the slide with a stain blocking agent; incubating the tissue with a primary anti-Peptide A antibody having an affinity for the N-terminal portion of the Metallopanstimulin; incubating the sample with chromogen stain; rinsing the sample; dipping the slide in a counterstain; mounting the slide for reading. Materials for performing the above steps are provided in a convenient, reasonably priced kit.Type: GrantFiled: July 29, 1998Date of Patent: July 8, 2003Inventor: Jose A. Fernandez-Pol
-
Publication number: 20030096315Abstract: A device and method for detecting the presence or absence of a prokaryotic microorganism are provided, comprising the steps of identifying a protein, such as a microbial-specific protease that characterizes the presence of a specific prokaryotic microbe and thereby provides a marker for that microbe; detecting the protease that is a marker for the presence of a specific prokaryotic microbe by cleaving a substrate when the protease is present; and signaling the presence of that protease when cleavage has occurred. More specifically, the method comprises identifying at least one outer membrane protein or a secreted protein that is unique to a particular microbial pathogen such as for example Listeria monocytogenes and that is substrate specific.Type: ApplicationFiled: May 3, 2001Publication date: May 22, 2003Inventor: Mitchell C. Sanders
-
Patent number: 6566054Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of mutant cyclin dependent kinase (CDK) proteins. These proteins fail to bind to CDK-inhibitory proteins and thus lead to aberrant cell growth. Herein, screening assays are described to identify CDK mutant proteins and the uses of these mutant proteins as tumor vaccines is described.Type: GrantFiled: August 30, 1996Date of Patent: May 20, 2003Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Manuel Serrano
-
Patent number: 6566084Abstract: This invention provides compounds which are analogs to the hydrolysis transition-state of a cocaine benzoyl ester group. This invention also provides such analogs linked to carrier proteins, and antibodies thereto. This invention further provides pharmaceutical composition for decreasing cocaine concentration in a subject using the antibodies produced.Type: GrantFiled: May 9, 2000Date of Patent: May 20, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Donald W. Landry, Kang Zhao